Trial watch: Toll-like receptor ligands in cancer therapy
ABSTRACTAccumulating evidence indicates that Toll-like receptor (TLR) agonists proficiently (re)instore cancer immunosurveillance as immunological adjuvants. So far, three TLR agonists have been approved by regulatory agencies for use in oncological applications. Additionally, these immunotherapeuti...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2180237 |